TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11101061
Drug: rhuIL-10 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuIL-10 4 microg/kg daily
Study: 8820468
Drug: Oral dolasetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dolasetron mesylate 50, 100, 150, 200, 250, 300, or 400 mg
Study: 20055898
Drug: Independent research
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Independent research programme on drugs funded by the Italian Medicines Agency (AIFA)
Study: 18374405
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy with alum-adsorbed grass pollen vaccine (Alutard SQ)
Study: 12645994
Drug: RWJ-270201 (BCX-1812)
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-270201 (BCX-1812) 100 mg/qd
Study: 12645994
Drug: RWJ-270201 (BCX-1812)
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-270201 (BCX-1812) 200 mg/qd
Study: 12645994
Drug: RWJ-270201 (BCX-1812)
Normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-270201 (BCX-1812) 800 mg on Days 1-5
Study: 2515342
Drug: Anti‐schistosomal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐schistosomal drugs plus prednisolone (Group II)
Study: 2515342
Drug: Anti‐schistosomal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐schistosomal drugs plus cyclosporine (Group III)
Study: 2515342
Drug: Anti‐schistosomal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐schistosomal drugs (Group I)
Study: 345749
Drug: Gradual reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual reduction of neuroleptic drugs (mean 75 mg equivalent of chlorpromazine)
Study: 345749
Drug: Maintained on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintained on matched dosages of neuroleptics (mean 150 mg equivalent of chlorpromazine)
Study: 345749
Drug: Gradual reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual reduction of neuroleptic drugs (mean 8 mg equivalent of chlorpromazine)
Study: 20177118
Drug: IM IFNbeta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM IFNbeta‐1a 30 microg once weekly plus placebo (n = 12)
Study: 20177118
Drug: IM IFNbeta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM IFNbeta‐1a 60 microg once weekly plus placebo (n = 11)
Study: 20177118
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice weekly (n = 22)
Study: 18950449
Drug: SGB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB with 10 administrations of 10 mg levobupivacaine every other day for 10 treatments, followed by one administration per month for 6 months
Study: 18950449
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg/day and gabapentin 1800 mg/day orally for 6 months, followed by SGB therapy in the 7th month
Study: 16669726
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Paroxetine + Psychotherapy)
Study: 16669726
Drug: Medication +
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication + Psychological therapy
Study: 12904810
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg tablet
Study: 9594180
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no THAM treatment)
Study: 3907641
Drug: 5,6-benzo-alpha-pyrone/troxerutin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,6-benzo-alpha-pyrone/troxerutin combination (Venalot Depot)
Study: 29735457
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate solution wet compress
Study: 12095495
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral hormonal contraception (Cileste: 250 microg of norgestimat and 35 microg of ethinylestradiol; Marvelon: 150 microg of desogestrel and 30 microg of ethinylestradiol)
Study: 10068412
Drug: Bedtime insulin
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime insulin plus metformin (2 g)
Study: 10068412
Drug: Bedtime and
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime and morning insulin
Study: 24216675
Drug: 5‐aminolevulinic acid‐mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐aminolevulinic acid‐mediated photodynamic therapy (ALA‐PDT) for lesions <0.5 cm
Study: 24216675
Drug: ALA‐PDT retreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA‐PDT retreatment after cryotherapy or CO2 laser treatment for lesions >2.0‐4.0 cm
Study: 16120070
Drug: Concomitant users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant users of analgesics
Study: 12399278
Drug: Phylloquinone supplementation
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone supplementation (500 micro g)
Study: 12399278
Drug: Phylloquinone supplementation
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone supplementation (1000 micro g)
Study: 12399278
Drug: Phylloquinone supplementation
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone supplementation (250 micro g)
Study: 12399278
Drug: Phylloquinone supplementation
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone supplementation (375 micro g)
Study: 9756471
Drug: Interferon-alpha-2b (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b (IFN) therapy at a daily dose of 5 million international units
Study: 9756471
Drug: Interferon-alpha-2b (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b (IFN) therapy at a daily dose of 10 million international units
Study: 9756471
Drug: Interferon-alpha-2b (IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b (IFN) therapy at a daily dose of 15 million international units
Study: 25434316
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (sugarless gum, half an hour three times daily after meals for 3 days)
Study: 25434316
Drug: High-dose senna
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose senna (150 mL senna solution, 300 mg senna the night before colonoscopy and 80 mg sennoside tablet daily for 3 days)
Study: 20938039
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg aspirin daily for 12 weeks
Study: 20938039
Drug: 162.5 mg
Normalized name: quinine 162.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 162.5 mg aspirin daily for 12 weeks
Study: 20938039
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin daily for 12 weeks
Study: 20938039
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg aspirin daily for 12 weeks
Study: 20938039
Drug: 1300 mg
Normalized name: gelatin 1300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1300 mg aspirin daily for 12 weeks
Study: 7607751
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (ramipril and enalapril)
Study: 364010
Drug: Fluoride solution
Normalized name: Apatate with Fluoride Solution
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride solution and/or silver nitrate treatment
Study: 24906665
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or placebo
Study: 19548447
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ganji recipe and FBE
Study: 1537519
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg chenodeoxycholic acid (CDCA)
Study: 1537519
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg UDCA
Study: 1537519
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg UDCA
Study: 1537519
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg UDCA
Study: 1537519
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg UDCA
Study: 1537519
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (no UDCA administration)
Study: 6375710
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of pindolol 10 mg and clopamide 5 mg
Study: 6375710
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of pindolol 10 mg and clopamide 5 mg
Study: 31165854
Drug: Chemotherapy use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy use
Study: 31165854
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for women aged 50 years and younger with RS 16-25
Study: 27621440
Drug: Treatment that
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment that framed healthy eating as consistent with adolescent values of autonomy and social justice
Study: 27621440
Drug: Treatment that
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment that framed healthy eating as consistent with adolescent values
Study: 22776871
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen twice before cycling
Study: 22776871
Drug: Cycling without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycling without ibuprofen
Study: 22776871
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen twice at rest
Study: 22776871
Drug: Rest without
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest without ibuprofen intake
Study: 22776871
Drug: Cycling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycling with ibuprofen
Study: 22776871
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen at rest
Study: 22776871
Drug: Rest without
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest without ibuprofen
Study: 9710040
Drug: rhIGF‐I 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I 0.1 mg/kg/day subcutaneously for 9 months
Study: 2470569
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusion for 28 consecutive days)
Study: 53719
Drug: Intramuscular insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular insulin (small doses)
Study: 53719
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of insulin (small doses)
Study: 53719
Drug: Large intravenous
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large intravenous boluses of insulin (control)
Study: 53719
Drug: Potassium requirements
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium requirements during treatment (both groups)
Study: 30868497
Drug: Intramuscular parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intramuscular parecoxib (40 mg)
Study: 30868497
Drug: 1% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% tetracaine gel (control group)
Study: 22981146
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 to 80 mg for 42 days (dyslipidemic patients)
Study: 22981146
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg for 21 days (non-patient volunteers)
Study: 18971794
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel 0.1% (1.0 mg/day)
Study: 18971794
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel 0.1% (0.5 mg/day)
Study: 18971794
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel 0.1% (0.25 mg/day)
Study: 2147834
Drug: Enoximone (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (3.6 mg/kg total dose over 3 hours)
Study: 28706331
Drug: Branded amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Branded amoxicillin capsule
Study: 28706331
Drug: Generic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic amoxicillin capsule
Study: 23986090
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily (monotherapy)
Study: 23986090
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg during 15 days intercalated with four 21-day cycles of docetaxel or pemetrexed (combination therapy)
Study: 15175564
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg daily)
Study: 30244028
Drug: Conventional multifactorial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional multifactorial treatment
Study: 27174405
Drug: Nonsplinted implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsplinted implants with ball attachment (BA)
Study: 27174405
Drug: Splinted implants
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Splinted implants with bar attachment (RA)
Study: 25531996
Drug: L. reuteri
Normalized name: L. reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. reuteri (DSM 17938)
Study: 17490972
Drug: Inadequate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate protein (IP) group; 0.5 g protein x kg(‐1) x d(‐1)
Study: 17490972
Drug: Control group;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group; 1.2 g protein x kg(‐1) x d(‐1)
Study: 16137086
Drug: Oxidized titanium
Normalized name: cobalt titanium oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxidized titanium implants (TiUnite)
Study: 8901853
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg beta-carotene and 25,000 IU retinyl palmitate (vitamin A) taken daily
Study: 1906634
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid producing bacteria (Lactobacillus acidophilus and Bifidobacterium bifidum) with 500 mg ampicillin t.i.d. for 7 days
Study: 1906634
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 500 mg ampicillin t.i.d. for 7 days
Study: 6319633
Drug: Stress Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress Management Program (SMP) consisting of eight weekly one-hour sessions of relaxation response, imagery, and diaphragmatic breathing; caffeine intake reduction
Study: 12782826
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding
Study: 26979433
Drug: Control (sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sucrose 50 g + deionized water 100 g)
Study: 22741171
Drug: Food-based intervention
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-based intervention to optimize dietary vitamin E intake to 15 mg/day
Study: 8643968
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m2 combined with carboplatin (AUC 6)
Study: 8643968
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m2 combined with carboplatin (AUC 6)
Study: 481481
Drug: Melphalan, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melphalan, cyclophosphamide, carmustine, and prednisone in concurrent schedule (Group C)
Study: 481481
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (A, B, C)
Study: 31131743
Drug: Long-duration treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-duration treatment (300 hours) with applied technology and motor learning.
Study: 25809877
Drug: solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: solifenacin 5 mg once daily
Study: 24010993
Drug: Valganciclovir (VGCV)
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valganciclovir (VGCV) dosing appropriate for most patients
Study: 24010993
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance <60 mL/min
Study: 17826341
Drug: Idebenone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (5 mg/kg, 15 mg/kg, and 45 mg/kg)
Study: 17826341
Drug: Idebenone (high-dose)
DrugBank: Idebenone (DB09081)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Idebenone (high-dose)
Study: 15036546
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid test
Study: 11753789
Drug: Oxaliplatin (l-OHP)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (l-OHP) plus 5-fluorouracil and leucovorin (5-FU/LV)
Study: 11753789
Drug: Oxaliplatin (l-OHP)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (l-OHP) in combination with 5-FU/LV
Study: 11753789
Drug: Oxaliplatin (l-OHP)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (l-OHP)
Study: 9028308
Drug: G‐CSF (granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (granulocyte colony‐stimulating factor) at a dosage of 5 micrograms/kg, starting the day after completion of the third cycle of chemotherapy.
Study: 6752872
Drug: Pirprofen 600
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen 600 mg/day
Study: 6752875
Drug: Ketoprofen 300
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 300 mg/day
Study: 20180611
Drug: No Proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Proton Pump Inhibitors (PPIs)
Study: 1337337
Drug: GM-CSF administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GM-CSF administration starting one day after chemotherapy for 7-10 days
Study: 1337337
Drug: GM-CSF administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GM-CSF administration after high-dose chemotherapy
Study: 1337337
Drug: GM-CSF administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GM-CSF administration after initial cycles of chemotherapy
Study: 27139019
Drug: No ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ice pack therapy (Control Group B).
Study: 20431422
Drug: CRAI (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRAI (continuous regional arterial infusion) with nafamostat mesylate 240 mg/d and imipenem 1 g/d for 5 days, followed by imipenem intravenously (0.5 g every 8 hours) for 9 days
Study: 19089223
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment in Class II/1 malocclusion patients (group T)
Study: 11808967
Drug: COX-2-specific inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2-specific inhibitor and traditional NSAID therapy
Study: 2823841
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU unfractionated heparin
Study: 7853952
Drug: 2000 anti-Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 anti-Xa IU low-molecular-weight heparin
Study: 29431028
Drug: Kindergartens where
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kindergartens where parents paid a monthly fee of 251 NOK or more
Study: 29431028
Drug: Kindergartens where
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kindergartens where employees paid a monthly fee to eat at work
Study: 29420395
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ulipristal acetate
Study: 29420395
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ulipristal acetate
Study: 14870949
Drug: Alcohol 0.5
Normalized name: isopropyl alcohol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.5 g/kg
Study: 1791932
Drug: Alcohol 0.3
Normalized name: ALCOHOL 0.3 TOPICAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.3 g/kg
Study: 9834924
Drug: Enteral formula
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral formula enriched with arginine, omega‐3 fatty acids, and RNA administered 7 days before and 7 days after surgery
Study: 18383334
Drug: Methacholine challenge
Normalized name: Methacholine Challenge Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine challenge (PC20 < or = 4.0 mg/ml) in girls